Comparing VivoSim Labs (NASDAQ:VIVS) and iSpecimen (NASDAQ:ISPC)

VivoSim Labs (NASDAQ:VIVS) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for VivoSim Labs and iSpecimen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1	0	0	0	1.00
iSpecimen	1	0	0	0	1.00

Profitability

This table compares VivoSim Labs and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
iSpecimen	-2,445.40%	-524.39%	-140.42%

Insider and Institutional Ownership

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by insiders. Comparatively, 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares VivoSim Labs and iSpecimen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130,000.00	28.59	-$13.84 million	($4.47)	-0.05
iSpecimen	$466,302.00	6.81	-$10.49 million	($56.44)	-0.02

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VivoSim Labs has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Summary

iSpecimen beats VivoSim Labs on 9 of the 11 factors compared between the two stocks.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.